Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00386646
Recruitment Status : Completed
First Posted : October 11, 2006
Last Update Posted : June 3, 2015
Information provided by:
Chulalongkorn University

Brief Summary:
To compare if 0.5% carboxymethylcellulose with 0.005% SOC (Stabilized oxychloro complex) have the same effectiveness and safety as 0.5% carboxymethylcellulose on dry eye patients.

Condition or disease Intervention/treatment Phase
Dry Eye Syndromes Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone Phase 4

Detailed Description:

Dry eye is the very common disorder of tear film. There are millions of people who have dry eye around the world. Dry eye patients may suffer from redness, sandy sensation, itching, excessive watering, burning sensation, excessive mucous discharge, blurred vision, contact lens intolerance, and increased risk of ocular surface damage and ocular infection. Currently, there is no curative treatment for dry eye. The mainstay of treatment is still artificial tear supplement or punctual occlusion. In moderate to severe dry eye patients, the standard replacement is using non-preservative artificial tear more than 4 times a day. However, non-preservative artificial tear has some limitation such as inconvenience to carry, expensive, ocular surface trauma due to sharp plastic tip.

Recently, there is improvement in using new disappearing preservatives in artificial tears. One of the new preservative is stabilized Oxychlorocomplex (SOC, Purite™) which can dissipate into water and sodium chloride, components of natural tears when exposed to light. It also has bactericidal and viricidal activities. Scanning electron microscopy also reveals that, carboxymethylcellulose (CMC) with SOC has a very low toxicity to corneal epithelium than other preservative.

The past study had documented that 0.5% CMC preserved with SOC was safe, comfortable and well tolerated for mild to moderate dry eye patients when applying 4-8 times daily.

The objective of this study was comparing efficacy, tolerability, and safety of 0.5% carboxymethylcellulose(CMC) with Stabilized Oxychlorocomplex(SOC) and 0.5% carboxymethylcellulose alone in patients with moderate to severe dry eye symptoms and/or signs.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial
Study Start Date : February 2004
Estimated Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Care
U.S. FDA Resources

Primary Outcome Measures :
  1. Rose Bengal staining

Secondary Outcome Measures :
  1. Fluorescein staining
  2. Total symptoms of dry eye
  3. Tear break up time (TBUT)
  4. Schirmer I test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Out patients of Ophthalmology department, King Chulalongkorn Memorial Hospital, who have symptoms and/or signs of dry eye
  • Bilateral dry eye symptoms and/or signs with equal severity between both eyes
  • Age > 18 years, capable of following the study protocol, and considered be able to return for all scheduled visit

Exclusion Criteria:

  • Different severity of dryness between both eyes
  • Current or recent use of topical ophthalmic medications that could affect dry eye condition
  • History of any systemic or ocular disorder or condition that could possibly interfere with the interpretation of study result
  • Recent contact lens wear (within one month)
  • Known hypersensitivity to 0.005% SOC or carboxymethylcellulose
  • Pregnancy or planned pregnancy
  • Having received permanent punctal occlusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00386646

Chulalongkorn Hospital
Bangkok, Thailand, 10330
Sponsors and Collaborators
Chulalongkorn University
Study Director: Pitipong Suramethakul, MD Faculty of Medicine, Chulalongkorn University, Bangkok Thailand
Principal Investigator: Vilavun Puangsricharern, MD Faculty of Medicine, Chulalongkorn University, Bangkok Thailand
Study Director: Nipaporn Maneerat, MD Faculty of Medicine, Chulalongkorn University, Bangkok Thailand

S. Rozen, M. Ableson, A. Giovanoni, et al. Assessment of the comfort and tolerance of 0.5% carboxymethylcellulose preserved with purite (REFRESH TEARSTM) in dry eye sufferers. Invest Ophthalmol Vis Sci. 1998 Mar 15;39(4)S451.
Peter J.McDonnell, John J.Doyle, Lee Stern, and The Dysfunctional Tear Syndrome Group Identifier: NCT00386646     History of Changes
Other Study ID Numbers: 152/2004
First Posted: October 11, 2006    Key Record Dates
Last Update Posted: June 3, 2015
Last Verified: October 2006

Keywords provided by Chulalongkorn University:
Dry eye syndromes therapy

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Carboxymethylcellulose Sodium
Gastrointestinal Agents